SUMMARY The levels of f32-microglobulin (52-m) in serum and urine of 24 seropositive patients with rheumatoid arthritis (RA) treated with regular gold (sodium aurothiomalate) injections have been investigated. The values obtained were compared with levels from 20 seropositive patients with RA treated only with nonsteroidal anti-inflammatory drugs and 20 age and sex matched normal controls who had received no medication. A significant increase ofurinary P2-m levels was found in the gold-treated RA group. No correlation between dose of gold received and the levels of 52-m in the urine could be established. There was also no correlation between the erythrocyte sedimentation rate (ESR) or total lymphocyte count and 52-m levels in serum or urine. We conclude that serum and urinary 52-m levels appear to be poor indices of joint inflammation, but sequential urinary t2-m levels may prove valuable in monitoring the development of renal tubular lesions due to gold therapy.
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P2-microglobulin (P2m), a low molecular weight protein (11 800), was first isolated from urine of' patients with renal tubular disorders.' Since then urinary P2m estimation has been regarded as an index of tubular reabsorptive capacity.2 Quantitative analysis of 52-m by radioimmunoassay is a sensitive method3 and has been widely used in screening for tubular dysfunction in general epidemiological studies4 and in studies on 'cadmium exposed' workers5, proteinuria being the first sign of the renal abnormality due to prolonged exposure to the heavy metal cadmium. 6 The proteinuria of cadmium toxicity has been considered to be tubular in origin, on the basis of a very high 52-m excretion despite only moderate increases in the total protein excretion, a characteristic of tubular proteinuria. 2 This study was carried out to investigate whether gold, also a heavy metal, may cause tubular dysfunction similar to that observed in cadmium toxicity and whether measurement of serum and urinary P2-m could be used to predict early renal dysfunction in the gold treated patients. Further, the value of determining levels of f2-m in serum and urine as an objective measurement-of inflammation in rheumatoid arthritis, as previously suggested,7 was also assessed. 
Results
There was a significant difference (P<0 05) in the urinary 52-m levels between the RA group on gold therapy and the RA group on nonsteroidal antiinflammatory drugs alone (Table 1 ). Significant differences (P<0 05) were also observed in the urine P2-m levels between controls and the RA group on gold therapy. There was no difference in the urine 32-m levels between controls and the RA group treated only with nonsteroidal anti-inflammatory drugs.
For the serum 52-m levels there was no significant difference (P>0 1) between the RA group on gold therapy and the RA group on nonsteroidal antiinflammatory drugs, but there was a significant difference between RA groups and controls (P= <0 01 for RA group on gold and P= <0 05 for RA group on nonsteroidal anti-inflammatory drugs).
There was a highly significant difference (P= 0-001) in ESR levels between the groups, but there was no correlation between the ESR and either serum or urinary 52-m levels. There were no significant differences between the total lymphocyte counts for each group, nor did the total lymphocyte count correlate with either serum or urine 52-m levels.
In the group of 8 rheumatoid patients on whom sequential measurements of serum and urinary 52-m levels were performed no significant change in the levels of 52-m in serum was seen after 6 months of regular gold injections (total dose 1200 mg) from that seen prior to gold therapy. The urinary and serum 52-m levels prior to gold therapy were not significantly different from those of other rheumatoid patients treated with nonsteroidal antiinflammatory drugs alone. The mean value for urinary 52-m levels rose from 104 ,ug/l to 183 ,ug/l during the 6-month period. Although because of the small number of patients involved these figures are not statistically significant, the urinary 52-m levels in these patients after 6 months of gold therapy was similar to the urinary 52-m levels in the 'goldtreated' patients (group 3).
T;ble 1 Creatinine clearance, serum 52-m, urine ,2-m, ESR, and total lymphocyte count in RA patients and controls. Proteinuria is a well recognised complication of gold therapy in rheumatoid arthritis and has been reported to occur in 1-11 % of gold treated patients.10 11 Both glomerular and tubular mechanisms may be involved. An immune complex nephritis due to gold salts has been described.12 13 Tubular involvement is known from the development of acute tubular necrosis during gold therapy.14 and the development of tubular lesions in gold treated animals. 15-'7 Further, it has been shown that gold inclusions appear in the proximal tubules within a few hours of administration of the drug,18 and that the proximal tubule is the major site of gold deposition in the kidney.19-2' Immunoglobulins and complement have also been demonstrated in the endothelium and basement membranes of renal tubules in immunofluorescence studies.12 Urinary P2-m estimation is said to be a sensitive index of tubular dysfunction in several diseases, including heavy metal toxicity.2 3 In our rheumatoid patients treated with gold urinary r2-m levels were found to be significantly raised when compared to the rheumatoid patients treated with nonsteroidal anti-inflammatory drugs alone. In fact the latter group had similar urinary 32-m levels to the normal controls, which implies that the high 52-m levels in the gold treated patients could well be related to the gold therapy.
Previous workers have suggested a correlation between serum r2-m levels and glomerular function,22 but not between serum and urinary 52-m levels. Glomerular function as measured by creatinine clearance was normal in all groups of patients in this study. However, the serum levels of P2-m were significantly higher in both groups of rheumatoid patients than in the control group, though there was no significant difference in the serum f2-m levels between the 2 rheumatoid groups. This would tend to support the view that the higher urinary f,2-m levels in the gold treated rheumatoid patients were neither due to differences in glomerular function in the gold treated rheumatoid patients, nor due to raised serum levels of r2-m per se, but rather to the gold therapy. However, the reason for the increase in urinary 52-m levels in gold treated patients may not be straightforward. Although the urinary P2-m levels in these patients were raised relatively to the controls and to the group treated with nonsteroidal antiinflammatory drugs, there was no apparent correlation between the urinary 52-m levels and either the duration of gold therapy or the total dose of gold administered. In the patients followed up sequentially serum and urinary P2-m levels before gold therapy were similar to those in the group not treated with gold. The mean dose of gold given to the 2 groups was also similar. The urinary P2-m levels after 6 months of gold therapy reached the levels seen in the 'gold treated' group (group 3), suggesting that gold was responsible for the rise in the urinary P2-m levels. It is probable that a sixmonth sequential study is too short, and it is hoped to continue this study for a further 3-year period.
The serum f2-m levels were significantly higher in both rheumatoid arthritis groups than in the controls, and this confirms the reports of other workers.7
A correlation between serum 32-m levels and (otal lymphocyte count has previously been reported in a group of 21 patients with RA. 7 We have been unable to confirm this finding. In fact we could establish no correlation between ESR values and levels of 52-m in either serum or urine or between the total lymphocyte count and 52-m levels in serum and urine. This would indicate that f32-m levels do not reflect inflammation per se and are not therefore useful as an objective measurement of inflammation. However, the finding of raised levels of 52-m in urine of patients on gold therapy may suggest slow or latent development of renal tubular dysfunction in some patients. It would seem to be important when studying 52-m levels in rheumatoid disease that adequate importance is given to the patient's drug therapy, as it is possible that other drugs may potentiate the tubular effect of gold. 
